Evidence map›Paper›PMID 38001023›Full record

ArticleBioinformatics (Oxford, England)2023

Multimodal learning in clinical proteomics: enhancing antimicrobial resistance prediction models with chemical information.

Giovanni Visonà, Diane Duroux, Lucas Miranda, Emese Sükei, Yiran Li, Karsten Borgwardt, Carlos Oliver

Abstract read
In one paragraph

Article in Bioinformatics (Oxford, England), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. [Advances in the Application of Artificial Intelligence in Clinical Microbiological Testing].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition · 2026
    Review
  5. Article
  6. Review
  7. Article
  8. PredictingmSystems · 2024
    Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Giovanni VisonàDepartment of Empirical Inference, Max Planck Institute for Intelligent Systems, Max-Planck-Ring 4, Tübingen 72076, Germany.ORCID 0000-0002-7878-5448
Diane DurouxBIO3-GIGA-R Medical Genomics, University of Liège, Avenue de l'Hôpital 11, Liège 4000, Belgium.ORCID 0000-0002-8564-3157
Lucas MirandaResearch Group Statistical Genetics, Max Planck Institute of Psychiatry, Kraepelinstraße 10, München 80804, Germany.ORCID 0000-0002-5484-6744
Emese SükeiDepartment of Signal Theory and Communications, Universidad Carlos III de Madrid, Leganés 28911, Spain.ORCID 0000-0002-8626-7026
Yiran LiDepartment of Biosystems Science and Engineering, ETH Zürich, Basel 4058, Switzerland.
Karsten BorgwardtDepartment of Biosystems Science and Engineering, ETH Zürich, Basel 4058, Switzerland.ORCID 0000-0001-7221-2393
Carlos OliverDepartment of Biosystems Science and Engineering, ETH Zürich, Basel 4058, Switzerland.ORCID 0000-0001-8742-8795

Funding

European Union's Framework Programme for Research and Innovation Horizon 2020Marie Skłodowska-Curie 813533-MSCA-ITN-2018
6 · The paper itself

Abstract

motivationLarge-scale clinical proteomics datasets of infectious pathogens, combined with antimicrobial resistance outcomes, have recently opened the door for machine learning models which aim to improve clinical treatment by predicting resistance early. However, existing prediction frameworks typically train a separate model for each antimicrobial and species in order to predict a pathogen's resistance outcome, resulting in missed opportunities for chemical knowledge transfer and generalizability.

resultsWe demonstrate the effectiveness of multimodal learning over proteomic and chemical features by exploring two clinically relevant tasks for our proposed deep learning models: drug recommendation and generalized resistance prediction. By adopting this multi-view representation of the pathogenic samples and leveraging the scale of the available datasets, our models outperformed the previous single-drug and single-species predictive models by statistically significant margins. We extensively validated the multi-drug setting, highlighting the challenges in generalizing beyond the training data distribution, and quantitatively demonstrate how suitable representations of antimicrobial drugs constitute a crucial tool in the development of clinically relevant predictive models. AVAILABILITY AND IMPLEMENTATION: The code used to produce the results presented in this article is available at https://github.com/BorgwardtLab/MultimodalAMR.

Indexed as

Anti-Bacterial AgentsProteomicsDrug Resistance, BacterialMachine LearningAnti-Bacterial Agents

Identifiers

PMID38001023
PMCPMC10724849

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.